Sanders TDI Participates in Discovery of New Anti-viral

A new study by the Tom Tuschl laboratory at The Rockefeller University and Sanders TDI introduces a proof-of-concept for a novel class of antivirals that would target a type of enzyme essential not just to SARS, but also many RNA viruses, including Ebola and dengue, as well as cytosolic-replicating DNA viruses, including Pox viruses. The findings, published in Nature,  may pave the way for a faster and more robust response to future pandemics.